TY - JOUR
T1 - PARP inhibition in the ovarian cancer patient
T2 - Current approvals and future directions
AU - Kurnit, Katherine C.
AU - Avila, Monica
AU - Hinchcliff, Emily M.
AU - Coleman, Robert L.
AU - Westin, Shannon N.
N1 - Funding Information:
KCK served on an Advisory Board for LEAP Therapeutics through the GOG-Foundation. RLC is a consultant for AstraZeneca, Clovis Oncology, GSK/Tesaro, Novartis, Roche/Genentech, Eisai, Merck, Pfizer, Novocure, Genmab, Gamamab, Oncosec, Tarveda. RLC receives research funding from AbbVie, Genmab, Merck, AstraZeneca, Clovis Oncology, Roche/Genentech. SNW is a consultant for AstraZeneca, Circulogene, Clovis Oncology, Eisai, GSK/Tesaro, Merck, Novartis, Pfizer, and Roche/Genentech. SNW receives research support from ArQule, AstraZeneca, Bayer, Clovis, Cotinga Pharmaceuticals, Novartis, Roche/Genentech, and GSK/Tesaro. All other authors have no conflicts of interest to report.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/9
Y1 - 2020/9
N2 - Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the therapeutic management of solid tumors, particularly ovarian cancer. Initially studied in BRCA deficient tumors, the Food and Drug Administration (FDA) indications have expanded to include other homologous recombination deficient tumors as well as biomarker-wildtype tumors. They have also gained momentum not only as a treatment strategy, but as a maintenance strategy as well. While PARP inhibitors were initially ev aluated in the recurrent setting, they have now moved to frontline therapy. This review will discuss the current FDA indications of the clinically available PARP inhibitors for treatment and maintenance therapies. We will then review the recently completed and ongoing clinical trials which may inform future clinical approvals.
AB - Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the therapeutic management of solid tumors, particularly ovarian cancer. Initially studied in BRCA deficient tumors, the Food and Drug Administration (FDA) indications have expanded to include other homologous recombination deficient tumors as well as biomarker-wildtype tumors. They have also gained momentum not only as a treatment strategy, but as a maintenance strategy as well. While PARP inhibitors were initially ev aluated in the recurrent setting, they have now moved to frontline therapy. This review will discuss the current FDA indications of the clinically available PARP inhibitors for treatment and maintenance therapies. We will then review the recently completed and ongoing clinical trials which may inform future clinical approvals.
KW - Clinical trials
KW - Ovarian cancer
KW - PARP inhibitors
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85085993770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085993770&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2020.107588
DO - 10.1016/j.pharmthera.2020.107588
M3 - Review article
C2 - 32450190
AN - SCOPUS:85085993770
SN - 0163-7258
VL - 213
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
M1 - 107588
ER -